市場調查報告書
商品編碼
1308630
2030 年生物可吸收聚合物市場預測:按產品類型、應用和地區劃分的全球分析Bioresorbable Polymers Market Forecasts to 2030 - Global Analysis By Product Type, Application, and By Geography |
根據Stratistics MRC 的數據,2023 年全球生物可吸收聚合物市場規模將達到15.2 億美元,預測期內復合年增長率為15.7%,到2030 年將達到42 億美元。預計將達到3000萬美元。
生物可吸收聚合物是醫療行業中常用的物質,因為它們可以被人體安全吸收。 一旦這些聚合物被植入體內,就不需要剝落。 另外,生物可吸收聚合物在醫療行業中的使用會降解生物可吸收聚合物,例如聚乳酸(PLA)、聚乙交酯(PGA)和PLA/PGA的共聚物。 對於將非結構化藥物輸送到可吸收螺釘和錨釘中,這些材料可以根據機械性能和吸收率進行定制,這將推動市場增長。
推動生物可吸收聚合物市場擴張的主要因素之一是許多外科手術的有利報銷情況。 例如,CMS USA 提供全球手術套餐,旨在支付所有手術護理費用,包括外科醫生為美國公民提供的術前、術中和術後護理。 因此,由於保險覆蓋範圍的擴大導致外科手術數量不斷增加,預計未來幾年生物可吸收聚合物的市場發展將會增長。
由於該領域的發展,基於生物可吸收材料的醫療產品的技術前景和應用正在迅速發展。 這要求醫生和其他醫療保健專業人員具備管理由生物可吸收材料製成的藥物的必要技能。 因此,外科醫生和醫療服務醫生不使用複雜的生物可吸收醫療產品來閉合傷口。
聚合物通過實現循環給藥、固定劑量治療劑的時間控制釋放以及親水性和疏水性藥物的差異釋放,極大地改進了藥物遞送技術。 自早期使用傳統材料以來,該領域已經取得了長足的進步。 現代藥物輸送領域的突破現在建立在針對特定貨物的聚合物的合理設計之上,旨在發揮獨特的生物活性。 生物可吸收聚合物能夠用配體進行表面修飾,從而實現隱私和人體內的靶向藥物輸送。 它還允許受控釋放到所需位置、對不平衡分子(例如蛋白質)穩定以及對不平衡分子穩定。
與可降解聚合物和其他聚合物相比,生物可吸收聚合物的市場在很大程度上受到其高成本的限制。 儘管預計該市場將以更快的速度發展,但與傳統聚合物市場相比仍然很小。 因此,傳統聚合物的生產受益於規模經濟,而生物可吸收聚合物的生產規模較小。 結果,製造成本增加並且對成品的需求增加。 然而,生物可吸收聚合物僅需要一次性處理,從而改善了整體服務。 從長遠來看,此類聚合物高成本的影響是可以減輕的。
鼠疫流行幾乎影響著文明的各個方面。 由於全球供應鏈中斷和規劃流程延遲,生物可吸收聚合物市場經歷了放緩。 醫療行業需求下降是這個問題的根源。 原材料供應短缺,貨物到達目的地需要很長時間。 然而,隨著醫療和製藥領域對生物可吸收聚合物的需求增加,市場開始復蘇。 疫情期間醫療行業繼續運轉,支撐了全球市場。 2021 年開展廣泛的疫苗接種運動後,更多發展中國家擴大了生物可吸收聚合物的生產。
聚乳酸部分由於其優異的加工性能和機械強度而預計將獲得利潤豐厚的增長,使 PLA 成為最具商業可行性的生物聚合物之一。 PLA 無毒、可生物降解、可回收、可堆肥並可被生物體代謝。 它們在許多方面都優於傳統聚合物,例如改進的熱加工性和各種成型工藝的可能性。 PLA 的兩個主要亞型是 PLLA 和 PDLLA。
預計骨科器械設備領域在預測期內復合年增長率最高。 這一應用的高速增長是由於骨科疾病的患病率不斷增加、人均收入增加導致生活水平不斷提高、醫療保健支出不斷增加、世界各國對更優質醫療保健和生物可吸收支架的需求不斷增加。多種因素,包括人們認識的提高
由於新興市場經濟快速擴張和人均可支配收入不斷上升,亞太地區預計將在預測期內佔據最大的市場份額。 印度、中國和日本等高增長國家、人口迅速老齡化、醫院數量不斷增加、支持性報銷政策、有利的政府舉措的實施、人均收入的上升以及對衛生部門的重大貢獻。尖端外科產品以及私立醫院向農村地區的擴張是推動亞太地區市場的其他因素。
由於骨科和藥物輸送應用中的產品使用量增加,預計北美在預測期內將呈現最高的複合年增長率。 北美生物可吸收聚合物市場受到醫療領域重要研發中心美國的進一步刺激。 此外,骨科和藥物輸送應用對聚合物的需求不斷增長以及醫療支出的增加預計將推動該地區的產品需求。
2023年6月,贏創將在新加坡建造一座新工廠,以在全球範圍內拓展其醇鹽業務。 未來,醇鹽催化劑也將通過在PET塑料的化學回收中的使用,在循環經濟中發揮重要作用。
According to Stratistics MRC, the Global Bioresorbable Polymers Market is accounted for $1.52 billion in 2023 and is expected to reach $4.23 billion by 2030 growing at a CAGR of 15.7% during the forecast period. Bioresorbable polymers are substance that is frequently utilised in the healthcare industry because it may be safely absorbed by the body. When these polymers are planted on the body, they do not need to be dethatched. Moreover, the utilization of the Bioresorbable polymers in the healthcare industry breaks down bioresorbable polymers such polylactide (PLA), polyglycolide (PGA), and copolymers of PLA/PGA. For the non-structural drug delivery to resorbable screws and anchors, these materials may be customised to match mechanical performance and resorption rates which drive the growth of the market.
One of the main factors propelling the expansion of the bioresorbable polymers market is the favourable reimbursement status for a number of surgical procedures. For instance, the US CMS offers the worldwide surgical package, which aims to cover payments for all surgical treatments which includes preoperative, intraoperative, and postoperative carried out by surgeons for US citizens. As a result, the market for bioresorbable polymers is anticipated to develop over the next few years as a result of the rising number of surgical operations brought on by better insurance coverage.
Due to developments in this area, the technical landscape and applications for medical goods based on bioresorbable materials are developing quickly. This urges doctors and other healthcare professionals to have the skills necessary to manage medicinal goods made of bioresorbable materials. As a result, sophisticated bioresorbable medical items are not used for wound closure by medical surgeons or doctors from healthcare services.
By permitting cyclic dosing, controlled release of therapeutic agents in constant amounts throughout time, and different releases of both hydrophilic and hydrophobic medications, polymers have considerably improved drug delivery technology. Since its early days of using ordinary materials, the field has substantially grown. Modern breakthroughs in drug delivery are now built on the rational design of polymers intended to exert unique biological activities and tailored for a particular cargo. Bioresorbable polymers have the capacity to change surfaces with ligands for privacy and targeted drug administration in the human body. They also allow regulated release to the desired place, stability to unbalanced molecules (such as proteins), and stability to imbalanced molecules.
The market for bioresorbable polymers is severely constrained by the higher cost of bioresorbable polymers compared to degradable and other polymers. Although the market anticipates a faster pace of development, it is still smaller than the market for traditional polymers. As a result, the manufacturing of traditional polymers benefits from economies of scale, whereas the production of bioresorbable polymers is small-scale. As a result, the cost of production is greater, boosting demand for the finished product. Bioresorbable polymers, however, provide a one-time fix and improved services overall. Long-term, this can lessen the impact of these polymers' greater cost.
The epidemic has had an impact on almost every facet of civilization. The market for bioresorbable polymers has seen a downturn as a result of the interruptions in the global supply chain and the delays in planned processes. The medical industry's declining demand was the root of this problem. Raw resources were scarce, and it took longer for goods to get where they were going. But when the demand for bioresorbable polymers was raised in the medical and pharmaceutical sectors, the market for them began to rebound. The medical sector continued to function during the epidemic, supporting the world market. Following the start of the widespread vaccination campaign in 2021, additional developing countries expanded the manufacture of bioresorbable polymers.
The polylactic acid segment is estimated to have a lucrative growth, due to its excellent process ability and mechanical strength, PLA is one of the most commercially viable biopolymers. PLA is non-toxic, biodegradable, recyclable, compostable, and is metabolised by living things. It is superior to conventional polymers in a number of ways, including improved thermal processability and the ability to be processed through a variety of moulding processes. The two primary subtypes of PLA are PLLA and PDLLA.
The orthopedic devices segment is anticipated to witness the highest CAGR growth during the forecast period, due to the major use of resorbable polymers is in orthopaedics. The high growth in this application is attributed to a number of factors, including an increase in the prevalence of orthopaedic disorders, an improvement in standard of living brought on by rising per capita income, rising healthcare spending, a rise in the demand for higher quality medical care, and increased awareness of bioresorbable stents in numerous nations around the world.
Asia Pacific is projected to hold the largest market share during the forecast period owing to the rapid economic expansion of developing nations and rising per capita disposable income. The presence of high-growth economies like India, China, and Japan, as well as the quick ageing of the population, the rising number of hospitals, supportive reimbursement policies, the implementation of helpful government initiatives, rising per capita income, significant investments in the healthcare sector, demand for cutting-edge surgery products, and the expansion of private hospitals into rural areas are additional factors driving the market in APAC.
North America is projected to have the highest CAGR over the forecast period, owing to rising product use in orthopaedics and medication delivery applications. The bioresorbable polymers market in North America is further fueled by the U.S., which serves as a significant centre for research and development in the healthcare sector. Additionally, it is anticipated that the expanding need for polymers in orthopaedics and drug delivery applications, together with rising healthcare spending, would drive up demand for the product in the area the expanding need for polymers in orthopaedics and drug delivery applications, as well as more healthcare spending, are all expected to drive up product demand in this region.
Some of the key players profiled in the Bioresorbable Polymers Market include Evonik Industries AG, Foster Corporation, Ashland Global Holdings Inc., REVA Medical, LLC, Bezwada Biomedical, LLC, BMG Incorporated, Foryou Medical Devices Co., Ltd, Musashino Chemical Laboratory, Ltd., Henan Xinghan Biotechnology Co. Ltd., KLS Martin Group, DSM Biomedical, Corbion N.V., Zeus Industrial Products, Abbott, 3D Biotek LLC, Sunstar Suisse S.A. and Futerro
In June 2023, Evonik launches new TEGO® Rad 2550 slip and defoamer additive for radiation-curing inks and coatings, The new TEGO® Rad 2550 is a clear, low viscosity liquid that effectively reduces static and dynamic surface tension in both conventional UV- and LED-cured formulations.
In June 2023, Evonik expands global alkoxides business with new Singapore plant. In future, alkoxide catalysts will also play a bigger role in the circular economy through their use in the chemical recycling of PET plastics.